Cancer Cachexia Market revenue to reach USD 4.5 Billion by 2036, says Research Nester
07 déc. 2023 06h00 HE
|
Research Nester
New York, Dec. 07, 2023 (GLOBE NEWSWIRE) -- The global cancer cachexia market size is predicted to grow at a CAGR of over 4.5% from 2024 to 2036. The market is projected to garner a revenue of USD...
RespireRx Pharmaceuticals Inc. Announces the 2nd Amendment to its License Agreement with the University of Illinois
23 janv. 2023 08h30 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Jan. 23, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compounds, Including Cannabinoids Such as Dronabinol
23 mars 2022 08h00 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
Cancer Anorexia Market Insights Report 2021 - Major Players are NGM Biopharmaceuticals, Artelo Biosciences and Helsinn Healthcare
08 avr. 2021 07h04 HE
|
Research and Markets
Dublin, April 08, 2021 (GLOBE NEWSWIRE) -- The "Cancer Anorexia - Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.This...
RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors
03 févr. 2020 09h00 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J, Feb. 03, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
Axim® Biotechnologies Begins Manufacturing Cannabinoid-Based Gum With Dronabinol for Use in Upcoming Pre-Clinical Studies
10 sept. 2019 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK , Sept. 10, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech,” “AXIM” or “the Company”) (OTCQB: AXIM), a world leader in cannabinoid research and development, announced...
AXIM® Biotech Enters Services Agreement With CRO to Begin Clinical Studies On Dronabinol and CBD Chewing Gums
09 avr. 2019 09h35 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, April 09, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC:AXIM), a world leader in cannabinoid research and development, today...
AXIM® Biotechnologies Appoints New Chief Executive Officer
08 janv. 2019 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Jan. 08, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced the...
AXIM Biotechnologies Advances Dronabinol Therapeutic Equivalence Program Through Purchase Agreement With Noramco
15 mai 2018 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has reached a long-term...
RespireRx Pharmaceuticals Inc. to Present at 10th Annual Biotech Showcase™ 2018
08 janv. 2018 08h45 HE
|
RespireRX Pharmaceuticals Inc.
CEO to Review completed Phase IIB dronabinol trial for the treatment of Obstructive Sleep Apnea (OSA) and Provide Pipeline update Glen Rock, N.J., Jan. 08, 2018 (GLOBE NEWSWIRE) -- RespireRx...